Navigation Links
GlaxoSmithKline Confirms Receipt of FDA Letter on Regulatory Reporting
Date:4/8/2008

LONDON and PHILADELPHIA, April 8, 2008 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today confirmed it has received a warning letter from the US Food and Drug Administration (FDA) related to reporting requirements for approved medicines. The letter follows a routine FDA inspection of GSK's reporting processes conducted last year.

The observations from the inspection primarily relate to omissions from periodic reports to the FDA regarding Avandia(R) (rosiglitazone maleate), such as the start and progress of clinical trials, and summaries of final data from some clinical trials.

The FDA inspection also reviewed GSK's processes for reporting individual adverse events, which resulted in no inspection citations. The inspection found nothing to suggest that procedures for prompt reporting of adverse events was compromised.

"We take these findings seriously, and corrective steps to make sure we file periodic reports completely and promptly have been taken or are underway," said Dr. Ronald Krall, Chief Medical Officer at GlaxoSmithKline. "These omissions did not interfere with the timely reporting of adverse event information to the FDA."

GSK is committed to taking the appropriate steps to address the concerns raised by the FDA.

After the inspection, GSK initiated a review of applicable processes and reporting systems. The company has made and will continue progress in updating its procedures and improving compliance in this area of reporting, including additional training for employees to ensure that all procedures are followed across all product lines.

The FDA letter acknowledges that information not captured in the periodic reports was, in many cases, submitted to the Agency in other reports an
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. GlaxoSmithKline Responds to JAMA Articles
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results
4. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
5. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
6. GlaxoSmithKline Aids California Fire Relief Efforts
7. Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
8. GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
9. Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds
10. GlaxoSmithKline Presents Innovative Neuroscience Pipeline
11. GlaxoSmithKline Receives FDA Complete Response Letter for Cervical Cancer Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... on October 9, 2007 --, BELLEVILLE, ON, Oct. 5 /PRNewswire-FirstCall/ - Bioniche Life Sciences,Inc., a ... field trial for its E. coli O157:H7 cattle vaccine,during a: ... & Audio Web Cast ... ...
... million Americans who experience the phantom sounds of tinnitus -- ... debilitating -- certain well-trained rats may be their best hope ... have studied the condition for more than 10 years and ... if they are experiencing tinnitus. , These scientists now have ...
... There are two aspects to creating an effective drug: ... effect and minimal side-effects and then delivering it to ... do its job., With the support from a $478,000, ... Harth is tackling the second part of this problem. ...
... company launches two oncology tests, SAN DIEGO, Oct. ... scheduled to provide a corporate overview of its molecular,diagnostic ... Conference. The presentation is scheduled for Thursday, November,1st, at ... the San Diego Marriott,Del Mar Hotel, 11966 El Camino ...
... 5 GENICON,and SIAD Healthcare S.p.A. announced today the ... SIAD Healthcare S.p.A. has made an,equity investment in GENICON. ... position on GENICON,s Board of Directors, which will be,filled ... August of 2006, GENICON and SIAD Healthcare S.p.A. entered ...
... Governor Edward G. Rendell,today joined the Pennsylvania Dental Association ... in recognizing October 5, 2007,as Senior Smiles Day in ... an individual,s overall,health and quality of life," Rendell said ... million adults over the age of sixty-five reside,in the ...
Cached Medicine News:Health News:Scientists search for brain center responsible for tinnitus 2Health News:Developing a modular, nanoparticle drug delivery system 2Health News:Developing a modular, nanoparticle drug delivery system 3Health News:SIAD Healthcare S.p.A. Acquires Minority Ownership in GENICON 2Health News:Governor Rendell Declares Senior Smiles Day in Pennsylvania; Goal is to Improve Oral Hygiene for Senior Citizens 2
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ... less than 10 bps, yet are surprisingly capable in ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... – Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Analysis Insulin Pumps ... as insulin delivery systems especially for type ...
(Date:1/15/2014)... NEW YORK , Jan. 15, ... a new market research report is ... Global Markets and Technologies ... Focus on Routes of Administration ... STUDY OBJECTIVES A ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... , THOUSAND OAKS, Calif., Nov. 5 Amgen (Nasdaq: ... PRIME "203" trial evaluating Vectibix® (panitumumab) administered in combination ... of metastatic colorectal cancer (mCRC) failed to meet a ... it was announced that the trial met its primary ...
... Partners today announced that it has been engaged by ... help roll out and promote it,s Calmare Therapy Treatment*, ... high-intensity oncologic and neuropathic pain, including pain resistant to ... to expand awareness of the brand and electromedical technology ...
Cached Medicine Technology:Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 2Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 3Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 4Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 5Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 6Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 7Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 8Competitive Technologies Selects RF|Binder as Public Relations Agency of Record 2Competitive Technologies Selects RF|Binder as Public Relations Agency of Record 3
Specimen-ID™, a Positive Specimen Identification System, assures the permanent link at the bedside between patient and laboratory specimen to prevent sample identification errors....
wCareMed™ utilizes barcode scanning technology to support medication administration. It is a simple to use point of care application that provides access to patient information on a lightweight,...
... Korchek Technologies CareChek ... employs barcode technology, Windows ... with integrated scanners (to ... at the bedside) and ...
... SafeRx, in conjunction with the AutoPPI barcoded ... formulated for a specific patient. The system ... to the correct patient and provides printed ... DrugTrack Manager keeps a record of the ...
Medicine Products: